BIOLASE, INC Form 8-K August 01, 2016

Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):	August 1, 2010

Biolase, Inc.

(Exact name of registrant as specified in its charter)

000-19627

(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
4 Cromwell, Irvine, California		92618
(Address of principal executive offices)	(Zip Code)	
Registrant s telephone number, including area code	»:	949-361-1200
	Not Applicable	
Former name or form	ner address, if changed since	e last report
Check the appropriate box below if the Form 8-K filing is intenthe following provisions:	nded to simultaneously satisf	y the filing obligation of the registrant under any o
Written communications pursuant to Rule 425 under the Se	ecurities Act (17 CFR 230.42	25)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

87-0442441

Edgar Filing: BIOLASE, INC - Form 8-K

Top of the Form

Item 2.02 Results of Operations and Financial Condition.

On August 1, 2016, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2016. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

- d) Exhibits.
- 99.1 Press Release of Biolase, Inc., dated August 1, 2016.

Edgar Filing: BIOLASE, INC - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Biolase, Inc.

August 1, 2016 By: David C. Dreyer

Name: David C. Dreyer Title: Chief Financial Officer

Edgar Filing: BIOLASE, INC - Form 8-K

Top of the Form

Exhibit Index

Exhibit No.	Description
99.1	Press Release of Biolase, Inc., dated August 1, 2016